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Figure 1: PI3K/AKT/mTOR and MEK pathway
INTRODUCTION
Colorectal cancer (CRC) kills over 50,000
people per year in the US. Current drug
therapy targets single intracellular pathways.
Activation of mTOR plays a key role in many
cancers. Over-activation of the pathway
mostly occurs from activation or mutation
upstream from mTOR, either from PI3K or
AKT. Mutations in the mTOR pathway have
been identified in roughly 30% of colorectal
cancers. Clinical data supports the use of
mTOR inhibitors as single agents, but
resistance to these agents can develop.
Previous studies show that the RAS
pathway was up-regulated in the colorectal
cancer (CRC) cell lines resistant to TAK228
when compared to the sensitive CRC lines.
Our objective was to find a new
combination using two current drugs,
TAK228, which targets mTOR, and
Trametinib which targets MEK in the RAS
pathway.
MATERIALS AND METHODS
IC50 (inhibitory concentration 50) was used 
to select 7 CRC cell lines (4 presented 
here). Cell lines were treated with varying 
concentrations of TAK228 and the MEK 
inhibitor Trametinib as single agents and in 
combination. Efficacy of drug combinations 
were measured using, proliferation and 
apoptosis assays such as Cell Titer-Glo, 
imaging with the Incucyte Zoom, and 
clonogenic assays. The downstream 
effectors were assessed by immunoblotting 
to determine the mechanism of the drug 
combination
• The combination of TAK228 and Trametinib inhibited 
proliferation in multiple CRC cell lines 
• As shown using both the Incucyte Zoom (Fig. 5) 
and clonogenic assays (Fig. 6)
• The combination of TAK228 and Trametinib
maintained tumor volume in SCID mice
• Immunoblotting shows a decrease in survivin, which 
may lead to an enhanced anti-proliferative response. 
• Immunoblotting also verified that the compounds 
were controlling their targets (MEK & mTOR)
• This control was maintained in the combination 
treatment (data not shown)
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Figure 3: IC50 values calculated from Cell Titer-Glo assay following 72 hours 
exposure to TAK228. GSEA analysis was performed on the six most sensitive 
(green line) and six most resistant (red line) CRC cell lines.
Figure 7: Immunoblot following 24 hour exposure to TAK228 (60nM) and Trametinib (15nM).
Figure 5: Apoptosis/Cell death and proliferation 
assay using Caspase 3/7 and Incucyte Zoom.
Figure 8: HCT116 cell line xenograft treated 
with TAK228 and Trametinib.
ACKNOWLEDGEMENTS
MEK
mTOR
LST8
rictor
mTOR
LST8
raptor
Trametinib
TAK228
Drug Targets
Figure 2: Targets of Trametinib and TAK228.
Figure 4: Proliferation assay using Cell Titer-Glo following 72 hour exposure to various 
concentrations of TAK228 and Trametinib.
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Figure 6: Cell recovery after drug wash out through a clonogenic
assay of CRC cell lines exposed to TAK228 and Trametinib for 72 
hours, followed by regrowth for an additional 72 hours.  Percent 
confluence was analyzed by ImageJ and graphed.
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